Search Results (29943)
Click the Why column to see why an item matched the search.
| Match | Type | Why |
|---|
| Leinwand, Leslie | Person |
Why?
|
| Allen, Larry | Person |
Why?
|
| Glasgow, Russell | Person |
Why?
|
| Matlock, Daniel | Person |
Why?
|
| Bryant, Stephanie | Person |
Why?
|
| CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. | Academic Article |
Why?
|
| Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. | Academic Article |
Why?
|
| Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas. | Academic Article |
Why?
|
| Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days. | Academic Article |
Why?
|
| Deletion of Cbl-b inhibits CD8+ T-cell exhaustion and promotes CAR T-cell function. | Academic Article |
Why?
|
| Fry, Terry | Person |
Why?
|
| Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML. | Academic Article |
Why?
|
| ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. | Academic Article |
Why?
|
| Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy. | Academic Article |
Why?
|
| Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. | Academic Article |
Why?
|